AN2 Therapeutics director receives 766-share stock grant

Martin Patricia A. reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Martin Patricia A. reported acquisition or exercise transactions in this Form 4 filing.

AN2 Therapeutics, Inc. director Patricia A. Martin received a grant of 766 shares of Common Stock on July 10, 2026. The shares were issued in lieu of cash fees under the company’s non-employee director compensation policy and vest immediately, bringing her direct holdings to 18,863 shares.

Insights

Equity Compensation Analyst

Routine equity grant to a director in place of cash fees.

Director Patricia A. Martin acquired 766 shares of AN2 Therapeutics common stock as compensation on July 10, 2026. The reported price per share was $0.00, indicating a stock grant rather than a market purchase.

The footnote states the shares were issued in lieu of cash under the non-employee director compensation policy and that all shares vest immediately. After this grant, Martin holds 18,863 shares directly. This appears to be a standard board compensation event rather than a discretionary open-market trade.

Insider Trade Summary

Grant/Award: 766 shares

Grant/Award 1 txn

Insider Martin Patricia A.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	766	$0.00	$0.00

Holdings After Transaction: Common Stock — 18,863 shares (Direct)

Footnotes (1)

1. F1. Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately.

Key Figures

Shares granted: 766 shares Grant price per share: $0.00 Shares owned after grant: 18,863 shares

3 metrics

Shares granted 766 shares Common Stock awarded to director on July 10, 2026

Grant price per share $0.00 Reported transaction price for the 766-share stock award

Shares owned after grant 18,863 shares Director’s direct holdings following the July 10, 2026 award

Key Terms

non-employee director compensation policy, in lieu of cash compensation, vest immediately

3 terms

non-employee director compensation policy financial

"issued in lieu of cash compensation under the issuer's non-employee director compensation policy"

in lieu of cash compensation financial

"Represents shares issued in lieu of cash compensation under the issuer's"

vest immediately financial

"All shares vest immediately."

FAQ

What did Patricia A. Martin report on her Form 4 for ANTX?

Patricia A. Martin reported receiving a grant of 766 shares of AN2 Therapeutics common stock on July 10, 2026. The shares were issued as board compensation rather than bought in the market.

How many ANTX shares does Patricia A. Martin hold after this transaction?

After the reported grant, Patricia A. Martin directly holds 18,863 shares of AN2 Therapeutics common stock. This reflects her updated position following receipt of 766 compensation shares.

Was cash paid for the 766 ANTX shares granted to Patricia A. Martin?

No, the 766 shares were issued at a reported price of $0.00 per share. They were granted in lieu of cash compensation under the non-employee director compensation policy.

Do the 766 ANTX shares granted to Patricia A. Martin vest over time?

No. The footnote states that all 766 shares vest immediately. This means the director has full ownership upon grant, without any multi-year vesting schedule.

Is Patricia A. Martin’s ANTX Form 4 transaction a market buy or sell?

Neither. The Form 4 shows an “A” code acquisition for 766 shares as a grant/award, issued instead of cash fees. It is not an open-market purchase or sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/10/2026 - 07:40 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Martin Patricia A.

(Last) (First) (Middle)

C/O AN2 THERAPEUTICS, INC.

1300 EL CAMINO REAL, SUITE 100

(Street)

MENLO PARK CALIFORNIA 94025

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AN2 Therapeutics, Inc. [ ANTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/10/2026		A		766(1)	A	$0	18,863	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately.

	/s/ Lucy Day, Attorney-in-Fact for Patricia A. Martin	07/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)